Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 8:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 14,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Egg Allergy
Interventions: Trivalent Influenza Vaccine; Biological
Lead sponsor: University of Michigan; Other
Eligibility: 6 Months to 24 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: San Diego, California • Ann Arbor, Michigan • Rochester, Minnesota + 2 more

Conditions: Primary Biliary Cirrhosis
Interventions: Saroglitazar magnesium 2 mg, Saroglitazar magnesium 4 mg, Placebo Oral Tablet; Drug
Lead sponsor: Zydus Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 9
States / cities: Pasadena, California • Miami, Florida • Marietta, Georgia + 5 more

Conditions: Metastatic Melanoma
Interventions: Masitinib, Dacarbazine; Drug
Lead sponsor: AB Science; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery
Interventions: Sugammadex, Placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 21 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Suicide, Suicide, Attempted, Suicidal Ideation, Alcohol Use Disorder, Alcoholism, Alcohol Abuse, Screening and Brief Interventions
Interventions: WisePath for Adults, Active-Control app + electronic wellness resources brochure; Device
Lead sponsor: Evidence-Based Practice Institute, Seattle, WA; Industry
Eligibility: 22 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Stroke, Ischemic Stroke, Stroke in Middle Cerebral Artery (MCA)
Interventions: ALD-401, Sham Procedure; Biological · Procedure
Lead sponsor: Aldagen; Industry
Eligibility: 30 Years to 83 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 9
States / cities: Los Angeles, California • Miami, Florida • Minneapolis, Minnesota + 6 more

Conditions: Attention-Deficit/Hyperactivity Disorder
Interventions: Centanafadine Hydrochloride, Placebo; Drug · Other
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 459 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Kidney Injury
Interventions: ABT-719, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 38
States / cities: Danbury, Connecticut • Gainesville, Florida • Jacksonville, Florida + 33 more

Conditions: Agitation in Patients With Dementia of the Alzheimer's Type
Interventions: AVP-786, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 111
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 78 more

Conditions: Atrial Fibrillation
Interventions: MAA868 Cohort 1, MAA868 Cohort 2, MAA868 Cohort 3, Placebo; Biological · Other
Lead sponsor: Anthos Therapeutics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 6
States / cities: Beverly Hills, California • Wichita, Kansas • Alexandria, Louisiana + 3 more

Conditions: Osteoarthritis of the Knee
Interventions: X0002, Placebo; Drug
Lead sponsor: Lina Xu; Industry
Eligibility: 35 Years to 85 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 20
States / cities: Tempe, Arizona • Carmichael, California • Spring Valley, California + 17 more

Conditions: Epilepsy
Interventions: USL261, Placebo; Drug
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 12 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 37
States / cities: Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 34 more

Conditions: Post-Traumatic Stress Disorder
Interventions: BI 1358894, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 37
States / cities: Little Rock, Arkansas • Glendale, California • Long Beach, California + 31 more

Conditions: Diarrhea
Interventions: Heat-Labile Enterotoxin of E. coli (LT), Placebo; Biological
Lead sponsor: Intercell USA, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: Anaheim, California • South Miami, Florida • Lenexa, Kansas + 2 more

Conditions: Huntington's Disease
Interventions: PF-02545920, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 22
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 12 more

Conditions: Thyroid Eye Disease
Interventions: Satralizumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: San Diego, California • Danbury, Connecticut • Chicago, Illinois + 3 more

Conditions: Recurrent Calcium Oxalate Kidney Stone Disease, Elevated Urinary Oxalate Levels
Interventions: Lumasiran, Placebo; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 17
States / cities: Birmingham, Alabama • Northridge, California • San Francisco, California + 14 more

Conditions: Atopic Dermatitis
Interventions: Crisaborole 2%, Vehicle; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 3 Months and older
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 25
States / cities: Fountain Valley, California • Fremont, California • Colorado Springs, Colorado + 20 more

Conditions: Psychosis
Interventions: Individualized imagery, Control; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Alveolar Bone Loss, Periodontal Diseases
Interventions: beta-tricalcium phosphate alone, GFeBGS 0.1%, GFeBGS 0.3%, GFeBGS 0.4%; Device
Lead sponsor: Sunstar Americas; Industry
Eligibility: 25 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 6
States / cities: Birmingham, Alabama • Fullerton, California • Aurora, Colorado + 3 more

Conditions: Pain, Acute
Interventions: S-Ibuprofen, Vehicle; Drug
Lead sponsor: Aponia Laboratories, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 251 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Plasmodium Falciparum Infection
Interventions: Chloroquine, PfSPZ (NF54) Challenge, Placebo; Drug · Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Type 2 Diabetes Mellitus (T2DM)
Interventions: LIK066, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Contraception
Interventions: Paragard® T380A Intrauterine Copper Contraceptive with New Inserter; Combination Product
Lead sponsor: CooperSurgical Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 119 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 8
States / cities: Denver, Colorado • South Miami, Florida • Atlanta, Georgia + 4 more

Search by objective public record fields.

Safe Administration of Flu Vaccine to Egg Allergic Children

Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis

Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit

Sugammadex and Decreased Time to Extubation

Drivers of Suicide Mobile App Study

Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects

A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder

A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery

Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

A Dose-range Finding Study of MAA868 in Patients With Atrial Fibrillation

A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis

Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU

A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder

Safety and Immunogenicity Study of Traveler's Diarrhea Vaccine Patch

Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease

A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels

A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis

The Effectiveness of Individualized Imagery Scripts on Sleep, Psychosis, and Suicidality Among Inpatients With Psychosis

GUIDOR® Growth Factor Enhanced Bone Graft Substitute for the Treatment of Periodontal Defects 6-months Post-Surgery

Controlled Study to Assess the Efficacy and Safety of S-Ibuprofen Topical Gel 5% (AP0302) in the Treatment of DOMS

PfSPZ Challenge in Healthy Malaria-Naïve Adults in the United States

Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)

A Study to Assess the Safety of a New Inserter Device for Paragard® (Intrauterine Copper Contraceptive)